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Introduction
In cardiovascular diseases, high total cholesterol (TC) and male sex usually 
associate with elevated risk. However, studies of aneurysmal subarachnoid 
haemorrhages (aSAHs), report paradoxically that low TC and female sex 
elevate aSAH risk. Additionally, no population-based studies on the risk factors 
behind the most-fatal aSAH: sudden-death aSAHs, exist. This thesis aims to 
unfold these two paradoxes and aims to characterize the risk factors of sudden-
death aSAHs using population-based cohort that includes also autopsy records 
of all sudden-death individuals. 
Methods
literature review and in hypothesis formation. The Preferred Reporting Items 
for Systematic reviews and Meta-analyses (PRISMA) check-list guided the 
reporting, and according to the Cochrane Collaboration guidelines, the review 
article focused on qualitative analysis because of high study heterogeneity. In 
cohort studies 65 521 population-based FINRISK participants were followed 
prospectively from medical registries since 1972 until the end of 2014. 
spinal tap, or at autopsy. Baseline measurements at enrolment provided risk 
factors and potential confounders for the analyses and multiple imputations 
supplemented the missing values. The Cox regression, adjusted for the 
main risk factors and confounders, provided hazard ratios and a platform 
associations between risk factors and aSAH during a long follow-up.
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Results
The systematic review found many high-risk-of-bias studies describing 
that low TC elevates aSAH risk, but it detected only two low-risk-of-bias 
studies, both indicating that high TC elevates aSAH risk. The cohort study, 
aSAH development especially in men. Smoking had a linear dose-dependent 
association with aSAH in both sexes, and ex-smokers had reduced aSAH risk 
when compared to smokers. However, although smoking elevated aSAH risk 
more in women, female never-smokers were not at elevated risk, indicating 
elevated risk. Along with high systolic blood pressure, smoking also elevates 
sudden-death aSAH risk more than it elevates risk for hospitalized aSAH. 
Conclusions
Methodological limitations in earlier studies explain at least in part the 
paradoxical, risk-increasing association between low TC and aSAH. An 
fraction of all aSAHs in men. Vulnerability to smoking explains at least in part 
the paradoxically higher aSAH risk in women observed earlier. All levels of 
smoking elevate aSAH risk, and reducing or quitting smoking both reduce the 
risk. Future studies should focus on clarifying whether improving the lipid-
aneurysm. In addition, they should study the reasons behind women´s 
death aSAH risk more than it elevates hospitalized aSAH, hospital-based aSAH 
studies may underestimate the role played by risk factors. Public health policies 
focusing on reduction in classic cardiovascular risk factors at population level 
are likely to reduce both hospitalized and sudden-death aSAH incidence.
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Johdanto
Kohonneen kokonaiskolesterolin ja miessukupuolen on usein kuvattu liittyvän 
suurentuneeseen sydän- ja verisuonitautiriskiin. Kirjallisuus kuitenkin 
paradoksaalisesti kuvaa näiden tekijöiden suojaavan sydän- ja verisuonitauteihin 
kuuluvalta aneurysmaattiselta lukinkalvonalaiselta verenvuodolta (aSAV). 
Myöskään vaarallisimman, äkkikuolemaan johtavan aSAV:n riskitekijöistä ei 
ole väestötason julkaisuja. Tämä väitöskirja pyrki selvittämään mainittujen 
paradoksien taustoja sekä ruumiinavaustietoja hyödyntäen kartoittamaan 
väestötasolla äkkikuolemaan johtavan aSAV:n riskitekijöitä. 
Menetelmät
Ensimmäisessä osatyössä artikkelien systemaattinen katsaus tunnisti 
väitöskirjan kannalta tärkeimmät artikkelit ja loi pohjan hypoteesien 
muodostamiselle. Artikkelien suurten keskinäisten erojen vuoksi katsaus 
keskittyi Cochrane-verkoston suositusten mukaan laadulliseen tarkasteluun. 
Tulokset raportoitiin systemaattisten katsausten ja meta-analyysien 
raportointisuosituksen (PRISMA) mukaisesti. Kohorttitutkimuksissa 
seurattiin terveydenhuollon rekistereistä 65 521 henkilöä, jotka osallistuivat 
FINRISK-tutkimukseen vuosien 1972 ja 2014 välillä. Uusi kohortti kerättiin 
joka viides vuosi, ja koko seurannan aikana tunnistettin 543 aSAV:a, joista 
98 johti äkkikuolemaan. Äkkikuolemaan johtaneet aSAV:t tunnistettiin 
Riskitekijät mitattiin seurannan alussa ja tutkimuksessa huomioitiin sekä 
aSAV:n tunnetut riskitekijät, että mahdolliset sekoittavat tekijät. Puuttuvat 
riskitekijätiedot täydennettiin tarvittaessa moni-imputaatiomentelmällä. 
Aineiston analyysissä käytettiin Coxin mallia, josta johdettiin riskitekijöiden 
hasardisuhde-estimaatit, väestön riskiosuus sekä multiplikatiiviset ja 
additiiviset efektin muunnokset, joilla tutkittiin riskitekijöiden vaikutuksen 
eroa miesten ja naisten välillä. Pitkän seuranta-ajan vuoksi analyysejä 
täydennettiin kilpailevien riskien mallilla, joka huomioi muista kuin aSAV:sta 
johtuneet kuolemat seurannan aikana. 
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Tulokset
Systemaattisessa katsauksessa havaittiin, että suuren harhariskin tutkimukset 
raportoivat aSAV:n riskitekijäksi etupäässä matalan kolesterolin, kun taas 
pienen harhariskin tutkimukset raportoivat riskitekijäksi korkean kolesterolin. 
aSAV:n riskitekijä etenkin miehillä. Tupakointimäärällä oli lineaarinen yhteys 
aSAV:in ilmaantuvuuteen sekä miehillä että naisilla ja riski lisääntyi mitä 
enemmän osallistujat polttivat, kun taas tupakoinnin lopettaneilla aSAV-riski oli 
seurannan aikana pienempi kuin tupakoijilla. Lisäksi havaittiin, että tupakointi 
lisäsi naisten aSAV-riskiä enemmän kuin miehillä, eikä tupakoimattomien 
naisten aSAV-riski ollut koholla tupakoimattomiin miehiin verrattuna. Tämä 
viittaisi siihen, että sukupuoli muuntaa tupakan ja aSAV:n välistä yhteyttä 
ja että tämä yhteys on voimakkaampi naisilla. Lisäksi tupakointi ja korkea 
verenpaine lisäsivät äkkikuolemaan johtavaa aSAV-riskiä enemmän kuin 
sairaalahoitoon johtavaa aSAV-riskiä. 
Johtopäätökset
Aiemmin havaittu paradoksaalinen yhteys matalan kolesterolin ja aSAV:n 
välillä selittyy ainakin osittain aikaisempien tutkimusten puutteellisilla 
miehillä että naisilla ja etenkin miehillä sen riskiosuus väestössä oli 
huomattava. Tulevien tutkimusten tulisi selvittää, voidaanko epäedullista 
aneurysma on jo todettu. Naisten herkkyys tupakan haitoille selittää ainakin 
osittain aiemmissa tutkimuksissa havaitun naisten suurentuneen aSAV-riskin. 
Jatkotutkimusten tulisi kartoittaa syytä miksi tupakka lisää naisten aSAV-
aSAV:n riskiä enemmän kuin sairaalaan johtavan aSAV:n riskiä, saattavat 
vain sairaala-aineiston sisältävät tutkimukset aliarvioida riskitekijöiden 
roolin. Kansanterveyspoliittiset päätökset, jotka johtavat klassisten sydän- 
ja verisuonitautien riskitekijöiden vähenemiseen väestötasolla, johtavat 
todennäköisesti niin äkkikuolemaan kuin sairaalahoitoon johtavan aSAV:n 
esiintyvyyden pienenemiseen.   
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ApoB  Apolipoprotein B
aSAH  Aneurysmal subarachnoid haemorrhage
BMI  Body mass index
CI  
CPD  Cigarettes per day
CT  Computer tomography 
HDL-C High-density lipoprotein cholesterol
HR  Hazard ratio
ICD
LDL-C Low density lipoprotein cholesterol
MI  Myocardial infarction
PAF  Population attributable fraction
RR  Risk ratio
SBP  Systolic blood pressure
SES  Socio-economic status
TC  Total cholesterol
TG  Triglycerides 
UIA  Unruptured intracaranial aneurysm
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Aneurysmal subarachnoid haemorrhage (aSAH), the third most common stroke 
type, comprises 3% to 7% of all strokes.1  As aSAH is, however, the most severe 
stroke type, the potential life-years of which it deprives a patient are similar to 
those of the most common type, ischemic stroke,2 which causes 67% to 82% 
of all strokes.1,3 Moreover, aSAH is also the most fatal stroke type; despite 
advances in invasive treatments, it still kills nearly 40% of those affected and 
leaves many survivors permanently disabled.4 It is also a very insidious disease: 
around 25% of incidental-aSAH patients die suddenly before being admitted to 
a hospital ward.5 Because aSAH affects participants younger than those with 
other stroke types,2,4 these sudden deaths often occur in asymptomatic and 
working-age individuals with no history of detected unruptured intracranial 
aneurysms (UIAs) or cardiovascular disease. Most aneurysms do not rupture, 
however, and invasive treatments of UIA and aSAH carry considerable risk for 
morbidity and mortality.6 These factors complicate UIA treatment decisions 
and emphasize the importance of identifying high-aSAH-risk subgroups and 
targeting invasive preventive measures for these individuals only. 
    In cardiovascular diseases, high total cholesterol (TC) and male 
sex usually associate with elevated risk. However, a number of aSAHs studies 
report paradoxically that low TC7-13 and female sex14-16 elevate aSAH risk. 
Currently, the well-established risk factors for aSAHs include increasing age, 
female sex, hypertension, and smoking,17,18 whereas studies on other traditional 
7-16,19-29 and physical 
inactivity30-36
association of smoking patterns in detail, and causes for elevated aSAH risk 
among women are yet to emerge. Additionally, to the best of the authors´ 
knowledge, no population-based studies exist on risk factors of sudden death 
from aSAH, even though, of all aSAHs, they comprise around 25%.5 This 
suggests that hospital-based studies not including sudden-death aSAHs may 
underestimate aSAH risk-factor estimates and nationwide aSAH incidences 
because of selection bias caused by exclusion of the sudden-death aSAHs. 
Because the strongest evidence suggests that preventable risk factors play the 
main role in aSAH development,37,38 this thesis focuses mainly on the interplay 
12
the lipid- and sex paradoxes in aSAH literature and describe the risk factors for 
aSAH in a population-based study by also using autopsy records of those who 
died suddenly outside hospitals.
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One way to classify intracranial aneurysms is to divide them into categories 
such as saccular, fusiform, dissecting (blood blister-like), mycotic, oncotic, 
and traumatic.39 Mycotic, oncotic, and traumatic aneurysms are secondary and 
result from infection, tumour, or trauma, whereas the fusiform aneurysm is rare 
and possibly has a distinct aetiology.39 This thesis focuses on aSAH resulting 
from saccular UIAs (referred to here as UIA), which are not secondary to a 
known cause and are the most common aneurysms, accounting for some 85% 
of all aSAHs.39 UIAs are mostly acquired degenerative dynamic lesions that 
may or may not grow and progress to aSAH depending on the individual risk-
40  Only a small fraction of UIAs are congenital and are related 
for example to connective tissue disorders.40 
UIA is a focal outpouching sac with a distinct neck that most often 
stems from artery bifurcations, usually near the circle of Willis.39 Approximately 
90% of UIAs arise in the anterior and 10% in the posterior cerebrovascular 
circulation.41-43 Outpouching begins when haemodynamic stress, usually 
aggravated by hypertension, exceeds the tensile strength in vessel walls.44 
The tensile strength of vessel walls decreases because of a complex interplay 
and altered nitric oxide production, each related to aSAH risk factors.44-46 This 
interplay can disrupt mural-cell function in vessel walls and offset the balance 
between processes of repair and degradation,44-46 and thus make vessel walls 
more vulnerable to haemodynamic stress. As UIA individuals age, their UIAs 
may or may not grow depending on the balance between these processes of 
repair and degradation in vessel walls. Through these mechanisms, risk factors 
such as smoking and hypertension can directly contribute to UIA formation 
and its rupture, which causes aSAH.46
In aSAH, the UIA bursts and releases blood into the subarachnoid space. 
Classical symptoms of aSAH include nausea, sudden and severe headache, 
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eye sensitivity to light, neck stiffness, decreasing cognition, and loss of 
consciousness.39 However, presentation of aSAH is insidious and ranges 
from isolated headache to sudden death.39 An aSAH may also cause focal 
neurological symptoms if the aneurysms bleeds into the brain parenchyma or 
compresses cranial nerves.39 Roughly 80 to 90% of aSAHs bleed from the 
anterior circulation, and the other 10 to 20% from the posterior circulation.47-49 
However, these reported ratios may change over time because of more frequent 
and accurate imaging studies that detect more and smaller aneurysms and 
because of better survival and higher age of aSAH patients.50 
aSAH cannot be diagnosed reliably with symptoms alone, and 
currently aSAH diagnosis relies on computer tomography imaging (CT). The 
increasing availability of CT in hospitals since the 1970s has led to better 
diagnostic accuracy of aSAH.51 Modern CT devices are reliable in aSAH 
detection and have a positive predictive value between 0.95 and 1.00 in 
symptomatic patients if CT is conducted within 6 hours of aSAH.39,51 However, 
blood in the subarachnoidal space that can be detectable with CT.18 If over 
six hours have passed from the beginning of symptoms, and CT is negative, a 
from aSAH.18,39 This can reveal aSAH up to 2 to 3 weeks after the onset.18 
Cranial vasculature, location, and the anatomy of the aneurysm can be then 
further studied most reliably with digital subtraction angiography.17,18,39
UIAs and ruptured aneurysms are commonly treated with 
neurosurgical clipping in which a metal clip is placed around the aneurysm neck 
or with endovascular coiling in which metal coils are inserted into the aneurysm 
sack.17,18,39 The purpose of both these methods is to isolate the rupture-prone part 
of an aneurysm from the circulation. The choice between the two methods is 
of the treating hospital.17,18,39 Since the late 1960s, developments in microsurgery 
and since the 1990s, developments in endovascular treatment of aSAHs have 
improved its prognosis considerably,52 and nowadays approximately one of 
every three aSAH patients can return to work.53 
Because aSAH is the most severe stroke type and occurs at a younger age 
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than do other strokes, it causes a considerable social and economic burden.2,4 
Nowadays, aSAH leaves approximately 40% of those affected dead, with many 
survivors left permanently disabled.4 The potential life-years of which aSAH 
roughly ten-fold more common but less severe.1,2 Studies on direct and indirect 
costs of aSAH are few; however, one German study estimated that within the 
38 000 € in direct and indirect costs. This cost depended on aSAH severity, and 
the German study reported that they excluded the most severely affected and 
costly aSAH patients. Based on their results, these authors estimated that the 
annual cost of all new aSAHs was 437 million euros in Germany.4 If we assume 
similar aSAH incidence and costs per patient, the very conservative estimate 
of new aSAHs per year in Finland would be roughly around 30 million euros. 
However, this estimate excludes most severe aSAH cases. Moreover, long-
term aSAH retirement and rehabilitation costs also remain high.54 
The estimated prevalence of UIAs ranges from 2% to 3%, but for certain 
individuals including women and those with detectable atherosclerosis, may 
be higher around 6%.17,18,41,55 Imaging studies nowadays often recognize non-
symptomatic aneurysms incidentally. Because the average annual rupture rate 
for aneurysms is only around 1.5%,42,47 preventive treatments should target 
individuals at high risk for aSAH if the aneurysms do not cause symptoms. 
However, the patient and aneurysm characteristics leading to aneurysm 
rupture remain controversial.56 The largest multicentre studies performed, the 
International Study of Unruptured Intracranial Aneurysms57 and the Unruptured 
Intracranial Aneurysm Study48 reveal that large aneurysms and aneurysms 
located in an anterior communicating artery, posterior communicating artery, 
or in posterior arteries predict the higher rupture risk. Additionally the studies 
reported that small (<7 mm) aneurysms are unlikely to rupture contrary to 
earlier evidence.56 However, many high-risk patients in these studies48,57 
underwent a surgical or endovascular aneurysm operation, which introduced 
a major selection bias that emphasized the role played by aneurysm size and 
reduced associations between risk factors and UIA rupture. In data-analysis, the 
studies48,57  used the Cox proportional hazards model, which assumes that the 
factors causing censoring do not relate to the outcome studied – an assumption 
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certainly not valid when most censoring is caused by high-aSAH-risk UIA 
operations. Additionally, the studies48,57  lacked blood-pressure measurement 
(a major aSAH risk factor), had a short follow-up, and had a low number of 
aSAHs; these further limit the reliability of their risk-factor estimates. An 
alarming indicator of potentially major bias was that when these studies were 
combined and reanalysed, a protective association between smoking (the most 
important aSAH risk factor) and UIA rupture risk emerged.47
The natural-history study of unruptured aneurysms from the 
Helsinki University Central Hospital58 is, to the best of the authors´ knowledge, 
the only study free of selection bias originating in treatment of high-risk UIA 
individuals, because it stems from an era before operative UIA management 
in Finland. Its cohort was collected between 1956 and 1978 and includes 
mainly individuals who had aSAH and multiple UIAs at baseline and whose 
unruptured UIAs were followed until death or aSAH. This cohort is clearly not 
an ideal population-based sample but can provide valuable information on the 
natural history of UIAs. Other advantages when compared to other studies in 
the cohort58 are pre-second-aSAH risk factors, a long follow-up, and repeated 
aneurysm imaging, which also allowed aneurysm growth analysis. Based on 
studies using this cohort, smoking, increasing aneurysm size, and aneurysm 
location in the anterior communicating artery elevate UIA rupture risk.59 In 
line with the least-biased epidemiological aSAH-risk factor studies,14-16 studies 
using this cohort also emphasize - in development of aSAH - the roles played 
by risk factors in addition to aneurysm size.42,59 Thus, in addition to patient 
and aneurysm characteristics, current European and American guidelines on 
management of UIAs recommend - in addition to UIA size - also considering 
SBP and smoking in UIA treatment decisions.17,18 However, routine screening 
with UIA or aSAH.17,18  This screening strategy has only a minor effect on 
aSAH incidence at population level and no effective risk-factor based UIA-
screening strategy yet exists.17,18  
Because studies on UIA individuals include only a few aSAHs, 
and nowadays many high-risk UIA individuals are treated during follow-up, 
population-based aSAH risk factor studies may offer the only way to reliably 
strategies and the ability to link electronic health records to cohort studies 
make population-based aSAH studies less prone to selection bias and offer 
considerably larger sample size. Thus, even in the absence of a UIA cohort, in 
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countries where aSAH diagnosis is reliable, population-based aSAH studies 
have the potential to enhance knowledge of factors leading to UIA rupture, 
17,18 
The generally accepted worldwide incidence of aSAH, derived mainly from 
studies done in high-income countries, is around 9.0/100 000.17,18 In middle- 
and low-income countries reliable estimates of this incidence are hard to 
collect because of a lack of resources needed to detect and diagnose aSAH 
individuals.60 Consequently, studies from these countries report both higher 
and lower aSAH incidence than those of high-income countries.1,60  However, 
if we assume a worldwide aSAH incidence of 9.0/100 000, 660 000 individuals 
worldwide will suffer from aSAH every year.60 
aSAH incidence, however, is not uniform and can differ between 
and within countries. Small non-population-based, and non-nationwide studies 
have reported that in Finland and Japan aSAH incidence is two-fold that of 
other countries.61 However, large nationwide population-based studies5,62,63 
varies considerably among different areas and age groups within one nation. 
These same studies5,62,63 indicate that incidence estimates derived from small 
nationwide incidence estimates, they are not valid. These studies may, however, 
serve to detect regional high-aSAH-risk subgroups. Apparently only Finnish, 
Swedish, Danish, and Norwegian studies64-67 include in their incidence estimates 
also sudden-death aSAHs (about 25% of all aSAHs). These population-based 
nationwide studies report fairly similar aSAH incidences of 8.9 to 12.0/100 
000.64-66 Large population-based studies from other industrialized countries 
provide similar aSAH incidence estimates which range from 8.0 to 13.7/100 
000.68-70 This indicates that, contrary to common belief aSAH incidence is not 
exceptionally high in Finland and suggest that nationwide Finnish aSAH studies 
may have fairly good external validity, and their results may be generalizable 
at least to other Nordic countries, and possibly more generally to populations 
of European ancestry. 
The incidence estimates may also change over time. Whereas 
stroke incidence has been reduced during the last 30 years in high-income 
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countries1 aSAH incidence has been more stable in studies conducted before 
2000.1,61
differentiate aSAH from other haemorrhagic strokes by means of improved 
quality of CT imaging may have played a role. After 2000, studies from Finland, 
Norway, Sweden, and Denmark report a between 11% and 24% decrease in 
aSAH incidence standardized for the European population. Between 1998 and 
2012, aSAH incidence in Finland has fallen 24% from 11.7/100 000 to 8.9/100 
000.5 During the same interval, smoking prevalence has decreased roughly 
9%, and mean SBP and TC have decreased roughly 3% and 5% in Finland.71 
Data from other countries with reliable aSAH incidence estimates also suggest 
similar trends. In Norway, between 1999 and 2007, aSAH incidence has 
decreased 20% from 11.1/100 000 to 8.9/100 000,64 and during this period the 
reductions in smoking prevalence, in mean SBP, and in TC have been around 
13%, 5%, and 7%.72,73 Nationwide studies from Sweden and Denmark report 
around 11% reductions in aSAH incidence, but these studies65,67 are older than 
the Finnish and Norwegian studies, which may in part explain the smaller 
reduction. 
The decrease in aSAH risk factors has occurred simultaneously 
with an increase in mean aSAH age. Studies conducted in the 80´s and 90´s 
report that aSAH incidence peaks around age 60,74 whereas studies after 
2000 from Norway and Finland describe a peak around age 70.5,64 aSAH 
incidence is higher in men before age 55, but after this, the incidence is higher 
in women.7,15,61 The main hypothesis is that menopause relates to higher 
aSAH rates in women through their decreased oestrogen levels,45,75 but this 
hypothesis remains untested in female humans. In general, aSAH incidence is 
low (< 2/100 000) before age 30 but then rises steadily until 70 to 75.64-66 After 
this, the incidence seems to somewhat decrease, possibly because individuals 
who survive to this age may have fewer aSAH risk factors. No new aSAH risk 
factors have emerged since the 80´s because current guidelines recognize only 
increasing age, hypertension, smoking, and female sex.17,18
When studying aSAH risk factors, one concern is the potential bias resulting 
from exclusion of the ~25% of aSAH individuals who die suddenly outside 
hospitals. This exclusion may bias the risk-factor estimates if the risk factors or 
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their associations in these individuals differ from that of hospital-based aSAH 
individuals. Therefore, when possible, this section focuses on studies that have 
included also sudden-death aSAHs. 
Epidemiologically, age is a measure of time since birth and thus per se is not 
a risk factor, whereas ageing refers to the cumulative effects of risk factors. 
Because of this, however, calendar age is a major confounder because it relates 
to many risk factors and their cumulative effect. Although population-based 
prospective studies describe increasing aSAH incidence as individuals age,64-67 
from other aSAH risk factors. These are factors that may lead to development 
to a damaged vessel wall, and to formation of rupture-prone aneurysms as 
individuals age.44
Epidemiologically, sex is also not an independent risk factor, but rather a proxy 
for biological differences between men and women. Studies consistently report 
elevated aSAH risk in women with HR ranging from 1.4 to 2.1,7,16,76 but the 
reasons behind the higher risk are still unclear. Effect estimates of some studies 
imply that hypertension and smoking can show differing association in women 
than in men14-16 but no well-powered studies have systematically studied this 
relates to changes in hormonal action and a subsequent decrease in oestrogen 
levels75 Supporting this theory is the observation that aSAH risk becomes higher 
in women post-menopausally after age 55.7,15,61 Another explanation for the sex 
that could lead to higher numbers of unrecognized sudden-death aSAH in men 
than in women. However, this is unlikely because studies from Nordic countries 
that include also sudden-death aSAH report similar HR estimates for female 
sex16 as do other studies.76 Thus the reasons behind the paradoxical association 
between female sex and aSAH remain to be studied.
The data on smoking and aSAH are rather consistent, with many prospective 
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studies reporting that smoking elevates aSAH risk with a HR between 2.2 
and 5.77,15,16,77 – a very strong association in the epidemiological context. 
However, these estimates are derived from current smokers, and because 
smoking rates decrease during follow-up,78 these baseline risk estimates are 
potentially underestimations. In addition, studies usually model smoking only 
as a binary variable, meaning that light and heavy smokers are included in 
the same category.7,15,16,77 This leads to an imprecise variable that potentially 
carries considerable residual confounding that can mask a potential effect 
estimates of cumulative smoking, measured for example in pack-years, ones 
that could capture life-time- and dose-response exposure to smoking and allow 
more detailed risk modelling, are few. Two retrospective case-control studies 
reported that smoking cessation reduces aSAH risk, but the risk may not be 
lowered among heavy smokers who quit.79,80 This would suggest that a critical 
limit for pack-years exists, and after exceeding this limit quitting smoking is 
the binary variables of hypertension and hyperlipidemia, their estimates may 
and long-term hypertension or hyperlipidemia. Thus, the data on association of 
smoking cessation and smoking habits with aSAH are still limited, and studies 
on dose response and effects of aSAH in different population subgroups are 
few. 
The strong association also has biological support, and the 
causal pathway from smoking to aSAH is thought to relate to every process 
of aneurysm formation.44-46  Smoking elevates wall shear stress by elevating 
blood pressure, and it causes increased blood viscosity. Inhaled toxins cause 
release of elastase that each further causes vessel walls to be more vulnerable 
to wall shear stress.44-46 In women, smoking also has the potential to reduce 
the protective effect of oestrogen.45 The elimination of these processes after 
quitting smoking is thus likely to lead to decreased aSAH risk.
Prospective studies on hypertension and aSAH also consistently report that 
diagnosed hypertension elevates aSAH risk with an HR between 1.7 and 
2.5.7,15,16,77 However, blood pressure elevates aSAH risk dose-dependently and 
the risk may be considerably higher with severe untreated hypertension.7,15,16,77 
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This indicates that the categorical hypertension variable is too inaccurate and 
imports considerable residual confounding into the risk estimates. In addition, 
antihypertensive medication may lower SBP and thereby reduce aSAH risk,81,82 
supporting the view that modelling of SBP instead of hypertension status 
may lead to more reliable risk estimates. Moreover, studies on hypertension 
in different population subgroups are limited, and no long-term prospective 
studies on effects of antihypertensive therapy on aSAH risk currently exist. 
During long follow-up, antihypertensive interventions may thus lead to 
decreased risk estimates for hypertension. 
The causal pathway from hypertension to aSAH is thought to 
relate to increased wall shear stress, endothelial damage, disturbance of smooth 
muscle cell function in vessel walls, and occlusion of vasa vasorum that leads 
to hypoxia and necrosis in vessel walls.44-46 By reducing these processes, 
hypertension treatment may reduce aSAH risk.
Some case-control studies and cohort studies have found an association 
between aSAH and alcohol consumption and some have not.7,16,21,77 Although 
amount of alcohol consumed and background characteristics in these studies 
have varied, most studies report elevated aSAH risk among heavy drinkers 
(>150 g of pure alcohol per week).7,16,21,77 The prevailing obstacle in studying 
associations between alcohol and aSAH is the limited number of heavy-alcohol 
consumers who do not smoke. This limits the ability to differentiate between 
the effects of alcohol and smoking; a further complication is underreporting 
of alcohol consumption.83 If heavy alcohol drinking is clustered among heavy 
smokers who also underreport their alcohol consumption, the HR of smoking 
Because alcohol consumption may also lead to hypertension and dyslipidemia, 
these may mediate the association between alcohol and aSAH,21 however, to 
the best of authors´ knowledge, no mediation studies on this subject exist. 
The suggested causal mechanism from heavy alcohol consumption 
to aSAH include damaged endothelium by elevated oxidative stress and wall 
shear stress caused by hypertension and elevated blood viscosity.44,45
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high15,25,28,29 and low7,9,11-13 TC to raise risk. Because case-control studies 
most case-control studies omit data on individuals´ previous risk-factor levels 
Cohort studies may be unable to control changes in lipid values during follow-
treatment. During follow-up, this inability to control for treatment may lead to 
because the widely used, most common lipid-lowering medication, statins, 
may have pleiotropic,84 vasculature-protective effects and can even reverse 
atherosclerosis.85
Meta-analyses have found no association between TC and 
aSAH, and suggest that high HDL-C may protect against aSAH.77,86,87 These 
meta-analyses summarize methodologically very different studies which 
have differing lipid measurement protocols, differing selection of cases and 
controls, and differing confounder adjustment and data analysis. Additionally, 
increased statin use after 1993 further complicates interpretation of meta-
analyses, because some of the cohorts included are from the pre-statin era, and 
some from the post-statin era.
Rat models suggest that the protective associations of 
hypercholesterolemia relate to enhanced cell maintenance and to 
decreased smooth muscle cell death.45 However, deleterious associations 
of hypercholesterolemia also have biological support. Atherosclerosis is 
commonly observable in aneurysm walls, with histological studies on human 
aneurysms suggesting that hypercholesterolemia associates with the elevated 
rupture.88,89
paradoxically, support from epidemiological studies.
Some studies report no association between aSAH and BMI,15,23,29,90 but most 
prospective studies show that low BMI elevates aSAH risk.7,14,16,91,92 The studies 
on BMI, however, have varying follow-up times, they control confounders 
differently, and they include different proportions of hospitalized aSAHs and 
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sudden-death aSAHs, which may in part explain the differences between 
such studies. In addition, because the excess the adiposity associated with 
93 and to the 
author´s best knowledge, no aSAH studies include mediation analysis of BMI, 
hypercholesterolemia, and hypertension, the true association and potential 
independent causal pathways between BMI and aSAH remain unclear.
Prospective studies on diabetes and aSAH are few, but case control 
studies describe no association or an inverse one.77,94 On several biological 
bases, this seems contradictory because diabetes elevates cardiovascular 
early stages of diabetic retinopathy are associated with retinal microaneurysms, 
which may in part have a pathogenesis similar to that of UIAs.95 However, the 
potential inverse associations may be associated with better control of smoking 
and hypertension as well as to higher rates of competing cardiovascular events 
related to diabetes.77 
Leisure-time physical activity associates with reduced risk for 
ischemic stroke,35,96 but only a few studies on aSAH and physical activity 
exist,30-36 and these present inconsistent results. The physical activity variables 
used in these studies differ considerably, and some add leisure-time, commuting, 
and occupational physical activity to overall physical activity, whereas others 
use only leisure-time physical activity.30-36
physical activity groups may be problematic because white-collar workers 
who are sedentary at work may have better health than blue-collar workers 
who are physically active at work and achieve high overall physical activity. 
high overall physical activity and aSAH if socio-economic differences are 
not controlled for. Moreover, some evidence indicates that different physical 
activity types may associate differently with cardiovascular diseases.96  In 
of hypertension development during follow-up. To the authors´ knowledge, 
mechanism among those physically active may also relate to reduced systemic 
97 44 
Since the suggestion of a familial predisposition for aSAH, several 
studies have sought for genes related to UIAs.38,98,99 However, associations 
between genes and aSAH remain modest38,98,99 and the concept of familial aSAH 
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remains controversial, especially since studies describing this association have 
failed to adjust their results for known aSAH risk factors that may also cluster 
in high-risk families.37 One large twin study further questioned the concept 
of familial aSAH by showing that heritability of aSAH is ~40%,37 which is 
lower than the heritability of coronary artery disease,100 (~50%) suggesting that 
aSAH does not carry an exceptional familial component.  Additionally, many 
genes that elevate cardiovascular disease risk act by elevating traditional risk 
factors such as LDL-C and SBP, 100,101 further complicating differentiation of 
direct genetic effects on the disease compared to mediation through risk factors, 
many of which have both a genetic and an environmental component.102 In the 
absence of large studies including repeated risk-factor measurements and of a 
suf cient number of aSAHs, the potential complex interplay between genes, 
risk factors, and aSAH remains undescribed. However, individuals with 2 
rst-degree family members with aSAH do have a high lifetime aSAH risk 
and may be the only reasonable group for UIA screening, despite current 
uncertainty regarding any aetiological pathway.17,18 
Other factors suggested to relate to aSAH are oral contraceptives, 
hormonal replacement therapy and polycystic kidney disease.77 Results on oral 
contraceptives and hormonal replacement therapy are con icting,103-105 partly 
because of unmeasured confounding, residual confounding, and differences in 
oestrogen and progesterone doses and their ratio. Earlier studies also speculate 
that polycystic kidney disease may elevate aSAH risk, however, current 
guidelines do not strongly support this.17,18
2.7 Common methodological problems
aSAH risk-factor studies are challenging to conduct for a number of reasons. 
Often the main issue is the limited sample size that results from low overall 
incidence and a high outside-hospital death-rate. Because only countries with 
a high coverage of forensic autopsies are able to detect comprehensively 
outside-hospital deaths from aSAH, reliable nationwide incidence estimates 
are rare and available mostly in the Nordic countries.64-67 Additionally, in aSAH 
risk-factor studies, exclusion of sudden-death aSAHs presents a potentially 
considerable selection bias in all case-control studies and in most cohort studies 
when autopsy records are not available especially if risk factors´ associations 
with hospitalized and sudden-death aSAH differ.
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Another problem, especially in case-control studies, arises from 
differing risk factor measurement methods in case and control groups which 
can lead to information bias and to reverse causality. For example, because 
aSAH is a severe disease and causes many physiological responses, in case-
control studies, the laboratory measurements performed at a hospital may not 
correspond to their pre-aSAH values.106 This has also been observed in studies 
on acute myocardial infarction (MI).107 aSAH patients are also often unable 
to provide reliable questionnaire-based pre-morbid risk-factor estimates 
because of their death or morbidity, which further lessens the reliability of 
case-control studies. In addition, those who suffer an aSAH (or their relatives) 
may become more aware of stroke cases in their families, which may cause 
recall bias108 in assessment of familial aSAHs. Additionally, if analyses fail 
to include commonly used medications such as statins and antihypertensive 
In cohort studies, confounding by indication may arise, because 
those who are high-risk individuals at baseline and during follow-up are more 
likely to receive health advice and medication. For example, if those with 
high TC at baseline receive cholesterol-lowering medication, the association 
between TC and aSAH could be attenuated or even reversed. In addition, few 
cohort studies can control risk factor changes over time, which may lead to 
all smokers quit during a long follow-up,78 which may weaken the association 
between smoking and aSAH. Moreover, the same risk factors that associate 
with aSAH are also associated with other cardiovascular diseases, and this 
can lead to an early end of follow-up because of competing causes of death. 
In aSAH studies using UIA cohorts, competing causes can also be surgical 
or endovascular interventions that reduce the risk for aneurysm rupture. This 
indicates that every aSAH risk-factor study should include a competing risks 
analysis, and this would be especially useful when studying the rupture risk 
of UIA cohorts in an era when surgical or endovascular interventions treat the 
high-rupture-risk patients. In this situation, an aneurysm operation becomes a 
competing event for aSAH meaning that the same risk factors that lead to an 
aneurysm operation are also related to aneurysm rupture rate, indicating that 
results omitting competing risks may be biased.
26
This thesis aims to understand the paradoxical associations between TC and 
aSAH and between female sex and aSAH and additionally aims to characterize 
of four goals: 
   associations of TC and aSAH by means of a systematic review. 
   population-based prospective cohort study that includes detailed   
   analysis by sex, and pre- and post-statin medication-era analysis.
  3) Characterization of any association between smoking habits and  
   aSAH in detail, and description of these associations in men and   
   women.
  4) Characterization of risk factors for sudden-death aSAH by   
   inclusion of data from autopsy records, and comparison of   
   the detected risk factors to those of hospitalized aSAH.
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The International Prospective Register of Systematic Reviews; (registration 
follows the Preferred Reporting Items for Systematic reviews and Meta-analyses 
for Protocols Statement. Cochrane Library, Pubmed, and Scopus databases 
provided the platform for the literature search with no language limitations, 
and native speakers assisted with non-English publications. We compared the 
to spot any differences in indexing or gaps in the preliminary search. Based on 
limitations in the preliminary search and on aid provided by an information 
comparison, outcome format was: Do low- or high cholesterol or lipoprotein 
levels associate with risk for aSAH in adults? The reference list of the second 
search was a platform for indirect validation of the results; we did not identify 
any new applicable studies from among the references. We ran the search for 
from the authors of 21 studies that had limited data for systematic review, only 
2 replied, indicating that individual personal data analysis was impossible. 
Study inclusion criteria were: 1) at least two categories for TC, 
LDL-C, HDL-C, or apolipoprotein concentrations with effect estimates, 2) at 
least 50 cases of aSAH. Based on Cochrane Collaborations recommendations,109 
we used the non-numerical Critical Appraisal Skills Program 110 and the 
Cochrane Collaboration Handbook109 in our risk-of-bias estimates. Our review 
scrutinized in particular, measurement bias, selection bias, reporting bias, 
confounder adjustment, reverse causality, and statistical power.
standard power value of P=0.8, correlation factor value of 0.1 between 
covariates, HR 2.0 (95% CI 1.0-4.0), and an incidence value of 20/100 000. To 
avoid too-optimistic associations, the random effect model provided I2 statistic 
and pooled risk ratios (RR) estimates in inverse variance weight meta-analysis. 
Population attributable fraction (PAF) estimation was done with following 
28
formula: PAF=pf (RR-1)/[pf (RR-1)+1], where pf indicates population fraction 
with hypercholesterolemia and RR relative risk. 
V
gathered data on independent, population-based, random samples of adults 
from various geographical areas of Finland. Surveys in 1972 and 1977 
comprised participants from North Karelia and North Savo, both located in 
eastern Finland.71 Since 1982, the Turku and Loimaa regions in southwestern 
Finland were also included, and from 1992 onward, the study comprised also 
the capital area of Helsinki and Vantaa in southern Finland.71 The provinces of 
North Ostrobothnia and Kainuu in northwestern Finland have also provided 
data since 1997.71 A 6.6% random sample of the population born between 1913 
and 1947 formed the cohort collected between 1972 and 1977. From 1982 to 
and 10-year age-group produced the cohorts.71 Since 2007, the corresponding 
age-group comprised those aged between 25 and 75. The participation rates 
were above 90% in the 1970s, have steadily decreased, but are above 60%  in 
the most recent surveys.71 The study methodology remained comparable in all 
surveys in order to achieve comparable cohorts. 
The population register of Finland provided information about 
collected data on the following variables: alcohol consumption, history of 
hypertension, medication for hypertension, medication for hyperlipidemia, 
physical activity, smoking status, marital status, and socio-economic status 
(SES) measured by years of education.71 Local study centres provided facilities 
for anthropometric measurement including height, weight, semi-fasting blood 
samples after at least 4-hour fasting, and systolic and diastolic blood pressure.71 
These measurements were performed by trained and experienced study nurses 
at enrolment. The venous blood samples were centrifuged on measurement 
sites and the sera were sent daily by mail to the laboratory of the National 
Public Health Institute for cholesterol measurements.71  Starting from 2007, the 
sera were frozen immediately after separation of serum and sent to National 
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Public Health Institute once a week for cholesterol measurements.71 
Mercury sphygmomanometers measured blood pressure in all surveys, and the 
cuff bladder size was 13 cm by 23 cm in 1972 and 1977, 13 cm by 42 cm from 
1982 to 1997, and was 14 cm by 36 cm   from 2002 to 2012.71 A minimum of 5 
minutes of rest preceded the measurements done from the right arm in a seated 
phase determined diastolic blood pressure.
Participants reporting smoking no more than between 0 and 100 cigarettes 
in their lifetime were considered never-smokers. Those who had smoked on 
a non-daily basis during the 6 months prior to enrolment were considered 
occasional smokers. Those participants who had quit smoking within 6 months 
before enrolment were recent quitters, whereas those who had quit over 6 
months before enrolment were former smokers. Current smokers provided the 
number of cigarettes smoked per day (CPD) on average separately for cigars, 
pipefuls of tobacco, and manufactured and self-rolled cigarettes. Because 
studies suggest that one cigar elevates aSAH risk as much as one cigarette, 
and one pipeful of tobacco as much as three cigarettes,111-115 we also included 
measurements indicate that the validity of self-reported smoking status is 
good, whereas cotinine levels and reported amount of smoking among smokers 
correlate only modestly.116
  We used eight categories of smoking status in our analyses: never-
smokers, occasional smokers, former smokers, recent quitters, and four groups 
of current smokers. Based on CPD, we divided smokers into 1 to 10, 11 to 20, 
21 to 30, and >30 CPD. We calculated pack-years for current smokers by the 
following formula: [(CPD x number of years smoked) / 20] and divided them 
into groups of none (for all but current smokers), <5, 5 to 10, and then in 10 
pack-year intervals until >50.
In 1972 and 1977, the Lieberman Burchard method served for analysis of 
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serum TC and triglycerides (TG) and from 1982 onwards, an enzymatic method 
(CHOD-PAP; Boehringer MANNHEIM, Mannheim, Germany)117 served for 
performing these the analyses. For all surveys, all pre-analysis procedures were 
the same.117,118 Dextran–MgCl2 precipitation, the enzymatic CHOD-PAP method, 
served for analysis of HDL-C between 1982 and 1997, and from 1998 onwards, a 
direct method served for the analyses.119 A direct method measured also LDL-C, 
and when LDL-C was calculable, it was also estimated by the Friedewald 
formula by limiting TG to <4.52 mmol/l. Because we had more LDL-C values, 
and because the Spearman correlation between directly measured LDL-C and 
Friedewald LDL-C was 0.96, we chose to use calculated Friedewald LDL-C 
in our analyses. In addition, the immunoturbidimetrical method of Abbott 
Architect reagents (Abbott Laboratories, Abbott Park, IL, USA) has served for 
measurement of ApoA1 (major lipoprotein in HDL-C) and ApoB (the primary 
lipoprotein in chylomicrons, VLDL-C, IDL-C, and LDL-C) since 1992.120 All 
values measured in FINRISK are under external quality control in order to 
avoid systematic errors.117 Data on lipid-lowering drugs were collected by self-
administered questionnaires.
The self-administered questionnaire collected data on the amount of alcohol 
consumed during the preceding seven days. The amount has been reported for 
each generally available alcohol type in Finland, including beer, wine, long 
drink, and hard liquor, since 1982. In 1972 and 1977, questionnaire-collected 
data involved only on beer and wine as well as total alcohol consumption. For 
analyses, we scaled the alcohol variable as absolute alcohol grams consumed per 
day.
4.2.6 BMI
Study nurses measured lightly clothed participants´ weight with a beam balance 
scale and rounded the result to the nearest 100 grams. In 1972 and 1977, height 
was rounded to the nearest 0.5 cm, whereas from 2002 onwards it was rounded 
to the nearest 0.1 cm.71 In our analyses, weight in kilograms divided by squared 
height in meters yields BMI. 
Baseline diabetes diagnoses were recorded by self-administered questionnaire 
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at enrolment, and during follow-up, the National Drug Reimbursement Register 
provided data on incident diabetes diagnoses. We had these data available for the 
Participants reported their years of education (used as a proxy for SES), which 
were then scaled to tertiles within each survey year because of changes in 
education duration during follow-up. Participants also reported their marital 
status in four categories: 1) married or cohabiting, 2) single, 3) divorced, 4) 
widowed. For analyses, we transformed marital status also into two categories: 
1) married or cohabiting, 2) without a partner (single, divorced, or widowed).  
covered follow-up only until December 31, 2011. For all participants who 
remained in Finland, the follow-up was complete, emigration during follow-up 
being rare.1 The nationwide Hospital Discharge Register and Causes of Death 
Register collected nonfatal and fatal aSAHs with high accuracy, covering also 
outside-hospital and emergency-room aSAH deaths.22 From these registries, 
with CT and/or spinal tap, whereas in addition to these methods sudden-death 
when the incidents occurred away from a hospital, in an ambulance, or in an 
emergency room. For all sudden and unexpected deaths outside hospital in 
Finland, a forensic autopsy is mandatory. A nosologist at Statistics Finland 
of death. The diagnosis protocol described yielded a positive predictive value 
of 87% for aSAH.121 The Strengthening Reporting of Observational studies in 
Epidemiology statement23 steers the reporting of all studies included.
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For values of ApoA1, ApoB, HDL-C, and LDL-C, the missing at random 
assumption122 applied, because study year alone explained missingness. For 
variables included in the imputation model, the percentages of missing values 
were: for smoking status 1.1%, SBP 1.6%, TC 1.9%, HDL-C 36.1%, TG 
41.1%, LDL-C 58.8%, ApoB 65.5%, and ApoA1 65.8%. Continuous variables 
in the imputation model were ApoA1, ApoB, BMI, HDL-C, LDL-C, SBP, 
and TC, whereas the categorical variables included were quartiles of alcohol 
consumption, eight categories of smoking, three categories of SES (measured as 
years of education), and use of a cholesterol-lowering drug as a binary variable. 
Linear regression imputed continuous-, ordered logistic regression imputed 
ordinal-, and logistic regression imputed binary variables. The imputation model 
smoking associates with aSAH more strongly in women.123 Our imputation 
lipoprotein variable and sex, hypertension, or smoking. Substantive-model-
does the ordinary fully conditional model.124 Our analysis used from 50 to 
150 iterations depending on convergence and 80 imputations to minimize 
simulation error. Based on imputation convergence analyses,125 our imputation 
analysis in which 10%, 30%, or 60% of the observed HDL-C, LDL-C, ApoB, 
model performed well even when 60% of data was missing. 
Students t-test calculated p-values for variables with normal distribution, while 
a Wilcoxon-rank test and chi square test calculated p-values for skewed and 
categorical variables. For unadjusted and adjusted models, the Cox proportional 
competing risks model126 calculated the associations in the presence of other causes 
of death during the long follow-up. When comparing differences in risk factors 
between sudden-death aSAH and hospitalized aSAHs, we compared the cause-
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variables. After reviewing prospective and population-based studies,7,15,16 we chose 
age, sex, smoking, SBP, and TC (or because of collinearity one of the following: 
to control for cohort effect. We also included self-reported cholesterol-lowering-
drug use, alcohol consumption, and years of education as proxy for SES into 
preliminary models. Between our variables and aSAH, we searched for non-linear 
associations with cubic splines and multivariable fractional polynomial models.127 
Inverse of HDL-C (HDL-C-1) associated more strongly with aSAH than did 
residuals and log-log plot inspection showed that proportional assumption criteria 
applied in our models. A likelihood ratio test tested multiplicative interactions 
128 provided 
relative excess risk due to interaction, attributable proportion, and synergy index 
in our adjusted models. A method restricting overall PAFs to 100%129 provided 
population-attributable fractions (PAFs) of the cases preventable by eradication 
of a risk factor. Stata Corp version 12.1 (College Station, TX, USA), and R 3.3.0 
served to perform all analyses.
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The local ethics committees gave approval for each FINRISK survey in 
accordance with legislation pertinent to the time of the survey. The World 
research also guided the studies. Each participant provided oral informed 
consent between 1972 and 1997, whereas from 2002 onwards, participants also 
gave a written informed consent.130
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Of the 21 studies 7-16,19-29 that met our inclusion criteria (Figure 1), 12 were 
prospective and 9 retrospective. Of the prospective studies, six originated from 
Adapted from PLOS ONE. 2016;11(4):e0152568, Lindbohm et al., “Cholesterol 
as a risk factor for subarachnoid hemorrhage: A systematic review,” by 
permission from Public Library of Science.
Figure 1. Flowchart describing how studies were selected for systematic 
review (Study I).
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Nordic countries (four from Finland, one from Norway, one from Sweden), 
three from the USA, two from Japan, and one from South Korea.7,13-16,19-25 Of the 
retrospective studies, four came from Japan and one each from the following 
countries: the USA, Portugal, South Korea, The Netherlands, and from a 
Denmark- and Great Britain-based collaboration.8-12,26-29
others had a high or moderate risk of bias (Figure 2). The two studies originated 
from Finland, although from different study groups. The oldest study14 included 
only very high TC values whereas the most recent study overlapped with the 
statin era. The main limitations in prospective studies were 1) absence of the 
25% of aSAH individuals who die outside hospitals, leading to selection bias, 2) 
lipid-lowering medication (Figure 2). The main limitations among retrospective 
studies were 1) exclusion of those 25% of aSAH individuals who die outside 
hospitals, leading to selection bias, 2) cholesterol measurement after aSAH, 
leading to risk for reverse causality, 3) selection of controls with potentially 
higher than average TC, 4) imprecise measurement of cholesterol by interview 
lowering medication (Figure 2).
The two low-risk-of-bias studies indicated that high cholesterol may elevate aSAH 
risk, at least in men. Because of differing study methodologies and considerable 
limitations in most studies reviewed, Study I was mainly a qualitative review. 
However, a meta-analysis of the most similar prospective studies supported the 
TC >7.00 mmol/l when compared to low TC < 4.90 mmol/l. However, the high-
risk-of-bias retrospective studies, which measured cholesterol by interview, 
suggested that low TC elevates aSAH risk with RR 0.42 (95%CI 0.19-0.95). 
One of the low-risk-of-bias studies also reported no association between HDL-C 
and aSAH. No prospective studies investigated associations between LDL-C or 
apolipoproteins and aSAH. If the low-risk-of-bias studies are indeed the best 
estimates of TC and aSAH, the PAFs for hypercholesterolemia could reach as 
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Figure 2. Risk of bias in all the 21 studies selected for review.
Adapted from PLOS ONE. 2016;11(4):e0152568, Lindbohm et al., “Cholesterol 
as a risk factor for subarachnoid hemorrhage: A systematic review,” by 
permission of the Public Library of Science.
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At enrolment, mean ages were 45.3 (SD 12.1) years for all participants and 
45.6 (SD 11.5) years for those who suffered aSAH. For aSAH cases, median 
follow-up time reached 14.8 years, and for the whole cohort 21.1 years. At 
enrolment, 38% of men and 17% of women smoked, and pack-years for current 
smokers at enrolment was 19.0 in men and 10.7 in women (Table 1). Female 
sudden-death aSAH individuals were older than those women with aSAH who 
reached hospital. Men who died suddenly from aSAH more often lived alone 
than did men hospitalized for aSAH (Table 1). 
   Total             Hospitalized  Sudden-death     p for  
  cohort     aSAHs       aSAHs difference
Men  31 716 205 46 
 Age at enrolment 45.1 (12.3) 45.8 (11.3) 46.4 (10.1) 0.62
 Age at end of 
 follow-up 67.3 (12.4) 59.9 (12.7) 59.3 (9.1) 0.76
 Alcohol (g/week) 82 (123) 94 (131) 133 (177) 0.36
 BMI (kg/m2) 26.5 (3.8) 26.1 (3.4) 26.2 (3.5) 0.81
 Cholesterol
 (mmol/l) 6.0 (1.3) 6.3 (1.4) 6.7 (1.3) 0.10
 SBP (mmHg) 143 (20) 146 (20) 149 (21) 0.40
 Smoking*    
    Never-
    smokers (%) 10 879 (35) 49 (24) 10 (23)  0.56
    Ex-smokers (%) 8 228 (27) 52 (26) 8 (19) -
    Smokers (%) 11 910 (38) 100 (50) 25 (58) -
    CPD  17.3 (9.6) 18.5 (8.7) 21.3 (10.7) 0.44
    Pack-years 19.0 (16.0) 21.0 (15.8) 29.0 (21.9) 0.33
 Marital status*    
   Married or 
   cohabiting (%) 24 317 (77) 161 (79) 29 (63) 0.03
   No partner (%) 7 324 (23) 44 (21) 17 (37) -
Table 1. Differences in baseline risk factors between sudden-death aSAH 
and hospitalized aSAH individuals. The table describes mean and standard 
deviation or number and percentages. 
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 Stroke in 
 either parent*    
   No    26 679 (89) 166 (83) 38 (84) 0.82
   Yes   3 248 (11) 34 (17) 7 (16) -
 Education*    
   Low   8 269 (27) 72 (34) 14 (31) 0.06
   Intermediate 10 915 (35) 66 (32) 22 (49) -
   High   11 826 (38) 72 (34) 9 (20) -
    Women 33 805 240 52 
 Age at 
 enrolment 44.9 (12.2) 45.7 (12.1) 47.9 (10.9) 0.25
 Age at end of 
 follow-up 69.1 (13.5) 61.9 (12.7) 66.9 (14.1) 0.01
 Alcohol 
 (g/week) 27 (50)  38 (82) 40 (60) 0.92
 BMI (kg/m2) 26.2 (4.9) 26.1 (4.8) 25.9 (4.8) 0.76
 Cholesterol 
 (mmol/l) 5.9 (1.3) 6.3 (1.4) 6.3 (1.4) 0.97
 SBP (mmHg) 139 (23) 146 (27) 151 (22) 0.35
 Smoking*    
   Never-smokers (%) 24 084 (72) 148 (63) 28 (56) 0.83
   Ex-smokers (%) 3 623 (11) 16 (7) 4 (8) -
   Smokers (%) 5 681 (17) 72 (31) 18 (36) -
   CPD   12.0 (7.1) 13.4 (6.7) 13.8 (7.0) 0.95
   Pack-years 10.7 (10.8) 11.9 (10.5) 10.0 (5.4) 0.85
 Marital status*    
   Married or 
   cohabiting (%) 24 692 (73) 166 (70) 30 (58) 0.09
   No partner (%) 9 040 (27) 72 (30) 22 (42) -
 Stroke in either parent*    
   No stroke in 
   either parent 28 051 (88) 195 (85) 42 (88) 0.63
   Stroke in 
   either parent 3 848 (12) 35 (15) 6 (12) -
 Education*    
   Low   10 034 (30) 78 (33) 14 (28) 0.44
   Intermediate 11 181 (34) 90 (38) 16 (33) -
   High  11 849 (36) 70 (29) 19 (39) -
*For categorical variables a single p-value for within group differences is provided.
Adapted from Stroke. 2017 Sep;48(9):2399-2404, Lindbohm et al., “Risk 
factors of sudden death from subarachnoid hemorrhage,” by permission of the 
American Heart Association, Inc.
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and ApoB values were on average more adverse after imputations in both sexes. 
This was expected because we imputed lipoprotein values for individuals who 
were from an era when average TC in Finland was higher. aSAH patients had 
more missing lipid values than did other participants because a larger proportion 
of them originated in an era when lipoprotein measurement methods were 
unavailable (Figure 3 A and B).
 Missing Cohort aSAHs Men  aSAHs  Women aSAHs
      in men  in women
TC 
(mmol/l)       1.9 % 5.97 (1.28) 6.32 (1.39) 6.03 (1.26) 6.39 (1.38) 5.92 (1.30) 6.26 (1.40)
HDL-C 
(mmol/l)      36.1% 1.42 (0.37) 1.36 (0.39) 1.28 (0.33) 1.24 (0.38) 1.55 (0.37) 1.47 (0.37)
LDL-C 
(mmol/l)     58.8 % 3.39 (0.94) 3.59 (1.02) 3.49 (0.95) 3.75 (1.10) 3.30 (0.92) 3.39 (0.89)
LDL-C        
(mmol/l) 
imputation       0 % 3.43 (1.07) 3.59 (1.19) 3.54 (1.06) 3.73 (1.18) 3.34 (1.08) 3.46 (1.18)
Triglycerides 
(mmol/l)      41.1% 1.49 (1.09) 1.59 (1.23) 1.73 (1.30) 1.86 (1.56) 1.28 (0.79) 1.34 (0.72)
ApoA1       
(g/l)     65.8 %    1.58 (0.30) 1.55 (0.33) 1.48 (0.26) 1.49 (0.33) 1.67 (0.30) 1.63 (0.33)
ApoA1           
(g/l) 
imputation      0 % 1.58 (0.29) 1.56 (0.31) 1.48 (0.26) 1.47 (0.30) 1.67 (0.28) 1.65 (0.29)
ApoB 
(g/l)      65.5% 0.97 (0.25) 1.02 (0.27) 1.02 (0.25) 1.07 (0.30) 0.93 (0.24) 0.96 (0.21)
ApoB           
(g/l) 
imputation       0 % 0.98 (0.28) 1.03 (0.29) 1.03 (0.27) 1.10 (0.28) 0.94 (0.28) 0.98 (0.29)
          
Table 2.
incident aSAH cases. (Means and standard deviations)
Adapted from Atherosclerosis, 2018 Jul;274:112-119, Lindbohm et al., 










































































Figures 3A and B. Percentage of imputed (light grey) and measured (dark 
grey) values among the whole cohort and among aSAH cases. Numbers in 
light grey columns: mean and standard deviation values after imputation; dark 
grey: before imputation. HDL-C and total cholesterol analyses included no 
imputation, and triglyceride imputation did not converge.
Adapted from Atherosclerosis, 2018 Jul;274:112-119, Lindbohm et al., 
population-based cohort study,” by permission of Elsevier B.V.
A) Cohort
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In our analyses, every SD increase in TC elevated aSAH risk 
only in men (HR 1.15, 95% CI 1.00-1.32). Every SD decrease in HDL-C 
elevated aSAH risk in the model, including both sexes (HR 1.20, 95% CI 
1.14-1.26), and this association persisted in both men (HR 1.20, 95% CI 1.14-
1.27) and women (HR 1.29, 95% CI 1.07-1.55) (Figure 4). The number of 
aSAH cases with measured LDL-C was too limited for reliable analysis. After 
imputations, in line with TC results, LDL-C elevated the risk only in men (HR 
1.14, 95% CI 1.04-1.25) (Figure 4). Competing risk analyses with complete 
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Figure 4.
deviation increase for each lipid variable from multivariate models (adjusted 
for age, sex, SBP, BMI, smoking, study year, and area) including imputations 
for ApoA1, ApoB, and LDL-C. Black indicates men and grey women, while 
y-axis presents hazard ratio scale. Units for ApoA1 and ApoB are g/l and for 
HDL-C, LDL-C, TC and TG mmol/l. 
Adapted from Atherosclerosis, 2018 Jul;274:112-119, Lindbohm et al., 
population-based cohort study,” by permission of Elsevier B.V.
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has a PAF of (33%, 95% CI 0-57%) which is comparable to PAFs of smoking 
(34%, 95% CI 23-44%) and hypertension (34%, 95% CI 0-57%). In women, 
the corresponding PAFs for smoking, hypertension, and TC > 5 mmol/l were 
22% (95% CI 19-25%), 49% (95% CI 30-64%), and 12% (95% CI -16-33%), 
indicating that smoking and hypertension but not TC play a major role in 
development of aSAH in women at population level. 
Complete-case analysis included too few participants with 
measurements of ApoA1 and ApoB values. After imputation, each SD increase 
in ApoA1 reduced aSAH risk in the model combining men and women (HR 
0.86, 95% CI 0.78-0.95). This association remained essentially the same in 
separate analysis of men (HR 0.88, 95% CI 0.76-1.02) and women (HR 0.85, 
95% CI 0.74-0.97) (Figure 4). In line with TC and LDL-C results, analysis 
of ApoB with imputed data showed that every SD increase elevated aSAH 
risk only in men (HR 1.26, 95% CI 1.10-1.44). Despite these differences, 
lipid variable and sex. All our HRs remained essentially the same in analysis 
including only the pre-statin era.
Moderate evidence supported elevated aSAH risk in recent quitters (HR 
1.93, 95% CI 0.98-3.79) and in former smokers (HR 1.34, 95% CI 0.98-1.82) 
compared to never-smokers. Female current smokers had a higher aSAH risk 
(HR 3.43, 95% CI 2.58-4.55) than did men (HR 2.20, 95% CI 1.56-3.10). 
Among heavy smokers, the HR in women was 8.35 (95% CI 3.86-18.06) 
compared to HR 2.76 (95% CI 1.68-4.52) in men (Table 3). This indicated 
as a linear dose-dependent association in both sexes (p=0.51 and p=0.30 for 
linearity departure in men and women). The association between baseline 
pack-years and aSAH was also linear in both sexes and stronger in women, in 
line with CPD results. 
higher life-time aSAH risk in female smokers than in male smokers (Figure 
and sex, female sex no longer elevated aSAH risk (HR 1.18, 95% CI 0.86-
1.62). Additionally, when compared to male never-smokers, female never-
smokers did not have an elevated aSAH risk, (HR 1.19, 95% CI 0.85-1.67) 
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further supporting the evidence that elevated aSAH risk in women is explained 
additive scale with relative excess risks due to interaction of 2.11 and 6.90 in 
women smoking 11-20 CPD and >21 CPD. 
Based on our review, all retrospective and most prospective aSAH studies 
exclude the approximately 25% of aSAH individuals who die suddenly outside 
hospitalized patients, the hospital-based studies may be unable to provide 
reliable risk-factor estimates and may fail to detect all aSAH risk factors due 
to selection bias. We thus studied the differences in risk factors between the 
98 sudden-death aSAHs and 445 hospitalized aSAHs included in our dataset. 
In relation to BMI, TC, and sex, no strong evidence of differences 
emerged between hospitalized aSAH and sudden-death aSAH. After controlling 
Table 3.  Risk for aSAH in the smoking categories in men and women. Model 
adjusted for age, SBP, BMI, total cholesterol, study year, and area.
Adapted from Stroke. 2016;47(8):1975-1981, Lindbohm et al., “Sex, smoking, 


















1  1  1  
Former smokers 
(quit over 6 
months earlier) 
1.34 (0.98-1.82) 60 1.26 (0.84-1.88) 47 1.14 (0.64-2.04) 13 
Recent quitters 
(less than 6 
months earlier) 
1.93 (0.98-3.79) 10 1.47 (0.59-3.67) 6 2.57 (0.94-6.97) 4 
1-10 CPD 2.54 (1.90-3.40) 63 1.93 (1.17-3.18) 22 2.95 (2.07-4.22) 41 
11-20 CPD 2.82 (2.14-3.70) 96 2.13 (1.46-3.11) 61 3.89 (2.63-5.74) 35 
21-30 CPD 3.79 (2.51-5.71) 30 2.76 (1.68-4.52) 23 8.35 (3.86-18.06) 7 
31 or more CPD 3.91 (1.97-7.75) 9 3.64 (1.79-7.40) 9 - 0 
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for the interaction between sex and smoking, female sex did not elevate aSAH 
risk in any analysis model. Interestingly, those who lived without a partner 
were at elevated risk only for sudden-death aSAH (HR 2.09, 95% CI 1.33-
3.28) (Table 4). Moderate evidence suggested that smoking elevates sudden-
death aSAH risk more than it elevates hospitalized aSAH risk (p=0.05). 
Sudden-death aSAH risk increased with increasing smoking rates and had HR 
5.04 (95% CI 2.22-11.44) in the >20 CPD group, whereas HR for hospitalized 
aSAH in the same group was 2.93 (95% CI 1.92-4.47). Moreover, moderate 
risk more than it elevated hospitalized-aSAH risk (p=0.05). The HR for every 
SD elevation in SBP was 1.34 (95% CI 1.09-1.65) for sudden-death aSAH 
Figure 5. Cumulative aSAH incidence in men and women by smoking status. 
Solid black lines: >30 CPD, dashed black: 21-30 CPD, solid dark grey: 11-20 
CPD, dashed dark grey: 1-10 CPD, solid light grey: former smokers, dashed 
light grey: never-smokers. Model adjusted for age, SBP, BMI, total cholesterol, 
study year, and area.
Adapted from Stroke. 2016;47(8):1975-1981, Lindbohm et al., “Sex, smoking, 
and risk for subarachnoid haemorrhage,” by permission of the American Heart 
Association, Inc.
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         All aSAHs        Sudden-death     Cases  Hospitalized     Cases  
              
         HR (95% CI)        (n)    HR (95% CI)      (n)  
        
BMI 
(per SD of 
4.4 kg/m2) 0.90 (0.81-0.99)  0.86 (0.68-1.09) 95 0.91 (0.81-1.01) 434 0.70
Cholesterol 
(per SD 
1.3mmol/l) 1.04 (0.95-1.15) 1.10 (0.88-1.37) 95 1.04 (0.94-1.16) 434 0.25
SPB 
(per SD 21.4 
mmHg) 1.27 (1.15-1.39) 1.34 (1.09-1.65) 95 1.25 (1.12-1.38) 435 0.05
Sex      
   Male 1 1 46 1 205 
   Female 1.31 (1.07-1.61) 1.45 (0.90-2.35) 52 1.31 (1.05-1.63) 240 0.68
Smoking      
   Never 1 1 38 1 197 
   Ex-smokers 1.37 (1.04-1.83) 1.35 (0.65-2.80) 12 1.37 (1.01-1.86) 68 0.91
   1-20 CPD  2.50 (2.00-3.12) 3.41 (2.01-5.79) 34 2.34 (1.84-2.98) 142 0.18
   Over 20 CPD  3.31 (2.28-4.81) 5.04 (2.22-11.44) 9 2.93 (1.92-4.47)  29 0.10
   per 5 cigarettes 1.21 (1.16-1.26) 1.28 (1.17-1.39) 81 1.19 (1.13-1.24) 367 0.05
Marital status      
   Married or 
   cohabiting 1 1 59 1 327 
   Single 1.09 (0.84-1.42) 1.85 (1.07-3.19) 18 0.99 (0.74-1.33) 58 0.04
   Divorced 1.56 (1.13-2.17) 2.83 (1.48-5.41) 12 1.33 (0.92-1.93) 32 0.05
   Widowed 1.34 (0.91-1.97) 2.15 (1.02-4.56) 9 1.24 (0.81-1.90) 26 0.17
Living status      
  Married 
  or cohabiting 1 1 59 1 327 
  No partner 1.25 (1.03-1.53) 2.09 (1.33-3.28) 39 1.01 (0.79-1.28) 116 0.006
Adapted from Stroke. 2017 Sep;48(9):2399-2404, Lindbohm et al., “Risk 
factors of sudden death from subarachnoid hemorrhage,” by permission of the 




Table 4. Risk factor differences between sudden-death and hospitalized aSAHs. 
Model is adjusted for variables presented (either marital status or living status).
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and 1.25 (95% CI 1.12-1.38) for hospitalized aSAH (Table 4). Cumulative 
incidence analysis supported these results and indicated that hypertensive 
smokers were at highest risk for both aSAH types, and that risk was lowest 
among normotensive never-smokers (Figure 6). Of all aSAHs included, 18% 
died suddenly outside hospitals. When compared to the reported 25% sudden-
death aSAH proportion in Finland, this was somewhat lower, indicating that 
our cohort may have been somewhat healthier than the general population.
Figure 6. Cumulative incidence of hospitalized aSAH (left) and sudden-death 
mmHg. Dashed black: smokers with SBP <140 mmHg, solid grey: never-
mmHg.
Adapted from Stroke. 2017 Sep;48(9):2399-2404, Lindbohm et al., “Risk 
factors of sudden death from subarachnoid hemorrhage,” by permission of the 
American Heart Association, Inc.
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Studies I, II, and III suggest resolutions of long-lasting debates on the 
female sex and aSAH. Additionally, to the best of the authors´ knowledge, 
population-based study. We found that methodological limitations are likely to 
explain why studies describe low TC as an aSAH risk factor. After minimizing 
these methodological limitations within the limits of our dataset, an adverse 
gaps in data analysis are likely reasons for the frequently observed association 
between smoking and sex. Furthermore, Study IV on sudden-death aSAH 
risk factors questions hospital-based studies´ ability to identify all aSAH risk 
factors and also suggests that hospital-based studies may underestimate risk-
factor effect sizes.
In Study I, the highest-quality evidence15,25 indicated that high TC elevates 
aSAH risk with some evidence of dose dependency, whereas the role played by 
HDL-C remained unclear. In addition, no study focused on LDL-C and only one 
retrospective study reported any association between ApoB and aSAH. One of 7-16,19-29 
Only two studies15,25 received low-risk-of-bias status; these studies did not include 
reliable statin data, but most of their follow-up occurred in the pre-statin era, which 
partially excludes the potential effects of statins. In light of the suggested Hills 
criteria of causality,131 these two studies15,25 had the most convincing temporality, 
biological gradient, plausibility, coherence, and analogy. The sensitivity analyses 
of studies15,19,22,24 which included the lowest number of limitations and somewhat 
comparable TC levels supported the two low-risk-of-bias studies. Other studies 
had major limitations in 1) exclusion of the 25% of aSAH individuals who die 
outside hospitals, leading to selection bias, 2) cholesterol measurement after aSAH, 
leading to risk for reverse causality, 3) selection of controls with potentially higher 
than average TC, leading to differences between compared groups at baseline, 4) 
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bias, 5) lack of analysis by sex, or 6) no data on lipid-lowering medication, leading 
to confounding by indication. If these two studies reliably describe the association 
between aSAH and TC, the worrying conclusion would be that based on detected 
prevalence of hypercholesteroemia,132 TC accounts for 17% to 35% of all aSAHs 
worldwide. In the high-TC regions such as Europe and the USA, the PAF would 
be 35% and 32%. 
literature revealed by Study I. Its results support the evidence provided by Study 
only low HDL-C and low ApoA1 elevated the risk. In our analyses, inverse of 
HDL-C had a stronger association with aSAH than did untransformed HDL-C. 
This suggests that in addition to other limitations, the studies included in Study 
I were unable to show any association between HDL-C and aSAH at least partly 
because they did not include testing for non-linear associations. In our analyses, 
proportionality remained unviolated, and the results remained the same in 
sensitivity analysis that included only the pre-statin-era. The PAF analysis was 
also consistent with that in Study I showing that high TC, high SBP, and smoking 
each account for one-third of aSAHs, at least in men.
These TC results seem reasonable, because high TC elevates 
cardiovascular diseases in general,133 and because atherosclerotic changes 
appear in aneurysm walls.44,89
smooth muscle cells88 - the important regulators of the balance between 
death and make the aneurysms prone to rupture.44,75 
The TC results observed in Studies I and II in men are in line 
with Systematic Coronary Risk Estimation risk charts described in the 2016 
European Guidelines on cardiovascular disease prevention in clinical practice.134 
abdominal aortic aneurysms, myocardial infarction, and stroke, 135-138 providing 
evidence that despite differing aetiologies, aSAH belongs to the atherosclerotic 
disease family. Moreover, when a large prospective Apolipoprotein-related 
Mortality Risk study138 combined intracranial haemorrhage and aSAH into the 
category of haemorrhagic stroke, some evidence of a protective effect from high 
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HDL-C in women emerged. Contrary to the Apolipoprotein-related Mortality 
Risk study,138 Study II was able to include smoking data, and to analyse aSAH 
separately form intracranial haemorrhage, which could explain the resultant 
stronger protective association of HDL-C in women. 
due to lack of power. However, if the differences indeed exist, they may result 
women are at lower cardiovascular disease risk than are age- matched men,133 
but physiological changes in menopause elevate cardiovascular disease risk,139 
and cause women´s TC and LDL-C levels to peak at approximately age 60.140 
Menopause additionally raises TG and reduces HDL-C, which also contributes 
140 aSAH incidence studies7,15 
and our competing risk models somewhat support this theory, because they 
describe aSAH incidence in women as exceeding that of men after age 55.7,15 
However, possibly because of the low number of pre-menopausal women 
with aSAH, we were unable to show any differences in aSAH in relation to 
menopausal status. In addition, PAF in Study II is based on the same population 
associates with aSAH differently in other populations.
However, these results have support from a study that was 
published after Study I and during the Study-II review process, which suggests 
that statin treatment reduced aSAH risk.141
similar to ours, the authors´ complete case analysis included only 10% of the 
study cohort, meaning that their results rely heavily on an imputation model 
that the authors did not validate. Additionally, those authors did not study non-
linear associations between lipid variables, had no data on duration of statin 
treatment, excluded high-aSAH-risk individuals by surgery or by endovascular 
coiling, and were unable to control SES that could relate to statin use and aSAH 
risk. Although those authors´ results are in line with ours, these limitations 
initiation of statin treatment for UIA patients.
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S
between smoking and sex, suggesting that elevated aSAH risk in women 
results from vulnerability to smoking. When the analysis excluded all smokers 
not an aSAH risk factor: results remained the same in all analysis models and 
in all age groups, with reasonable power. When we used the same analysis 
protocol as that of earlier studies which consistently describe elevated aSAH 
risk in women,7,15,16,142 female sex returned as an aSAH risk factor. This was 
in binary smoking and SBP variables. We also showed, in line with earlier 
sexes.79,80,143 Even 1-10 CPD elevated aSAH risk, but risk decreased after 
smoking cessation in both sexes, as observed in earlier case-control studies.79,80 
These results also persisted in analysis including competing risks. 
decreased risk after smoking cessation.144,145 and by describing a dose-dependent 
association between smoking and both outcomes.144,146 However, one recent 
study, which was published after Study III, suggests that smoking cessation 
does not diminish aSAH risk.147 That study used a hospital-based cohort, which 
excluded all treated aneurysm patients – the ones at the highest aSAH risk. 
Moreover, that study did not include any measure of time in its analyses and 
did not perform competing risks analysis. Such an approach limited their ability 
to study risk factor changes over time and to take into account the competing 
risk by aneurysm treatment. Additionally their multivariate analysis included 
many variables with potential collinearity, such as coronary artery disease, 
years smoked, and age. These limitations may have biased their results, as 
suggested by the opposite HRs of female sex, family history of aneurysms, age 
at diagnosis, and coronary artery disease147
aSAH studies.14-16,148 Associations between smoking cessation and aneurysm 
rupture when an aneurysm is already present thus demand more research in a 
when considering patients` overall prognosis. 
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is supported by studies on myocardial infarct.149,150 The deleterious effect of 
smoking may relate to decreased oestrogen levels. Smoking can directly reduce 
oestrogen level and even further reduces it by inducing early menopause.151,152 
dysfunction of mural cells in vessel walls,75 which is a major degrading cascade 
in vessel walls.44,46 These changes may then contribute to aneurysm formation 
and aSAH.46 
SBP and smoking elevated risk for sudden-death aSAH just as they elevate risk 
elevate sudden-death aSAH risk more than they elevate hospitalized-aSAH 
risk, and that those who live alone are at elevated sudden-death aSAH risk. 
All the associations were similar in both sexes, but the number of sudden-
and that hospital-based studies may not include those at highest aSAH risk. 
Hospital-based studies may thus somewhat underestimate aSAH risk factors 
suggesting that current UIA-treatment guidelines17,18 may underestimate the 
role played by risk factors. Additionally, the reason that hospital-based studies 
may not detect all aSAH risk factors may be in part selection bias. 
Studies on sudden-death myocardial infarct153,154 support our 
myocardial infarct than in hospitalized myocardial infarct patients. Our 
also have more comorbidities that could lead to a higher mortality rate at the 
onset of aSAH. The elevated risk among those who live alone may also relate 
to social isolation and to more adverse development of health and risk factors 
during follow-up than for those who live with a partner.155 Another possible 
explanation for elevated aSAH risk in those who live alone is that, because 
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of disabling symptoms of aSAH and lack of potential helpers, they are less 
likely to receive medical attention. This could be a plausible explanation if 
aSAH behaved like sudden-cardiac deaths of which 80% occur at home, with 
of those only 60% being witnessed.154 Thus, individuals carrying a UIA and 
and social support and possibly also from different treatment approaches 
from those approaches for those who live with a partner or spouse. Finally, 
even though our cohort had a good participation rate, we cannot exclude the 
possibility that selection bias led to underestimation of associations between 
sudden-death aSAH and risk factors if those with the most severe risk factors 
and a potentially higher aSAH rate did not participate.
Study I had an extensive search strategy which provided 21 studies with over 50 
aSAHs. When compared to earlier systematic reviews identifying only seven,87 
six,77 and three156 studies with a total of over 50 aSAH cases, Study I is the most 
extensive to date. Moreover, contrary to previous systematic reviews, Study I 
a quantitative summary as recommended by the Cochrane Collaboration when 
considerable methodological differences are present in the studies selected.109 
In Studies II to IV using the FINRISK cohorts, a comprehensive 
than was possible in earlier studies. FINRISK cohorts collected from different 
decades also allowed us to take into account potential confounding of statin 
medication by separate analysis of pre- and post-statin eras. Additionally, when 
compared to earlier studies, our Studies II, III, and IV had robustness in long 
reducing the risk for selection bias. All our data were collected at baseline, 
reducing risk for information bias and reverse causality. Additionally, the 
FINRISK questionnaire on smoking habits was more extensive than those ones 
used in earlier studies, enabling us to describe the association between smoking 
and aSAH in detail. Contrary to most earlier studies, smoking status in the 
FINRISK cohorts has also been validated against cotinine measurements.116 
Additionally, with the detailed death records in Finland we were able to 
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include out-of-hospital aSAH deaths with a high 80% autopsy rate, and with 
157 To the authors´ 
death aSAHs and thus offer low risk for major selection bias, suggesting that 
our results may be more reliable than are those acquired from earlier cohort 
studies.  
Despite its exhaustive search strategy, Study I may lack some relevant 
publications due to limitations in the search strategy and to indexing errors. 
It also includes a study by two of its authors (M.K. and J.K.) which could 
To compensate for these limitations, the International Prospective Register 
of Systematic Reviews
Study I also lacks reliable meta-analysis because of differences and limitations 
in studies reviewed and because of lack of individual patient data. In Study 
II the proportion of missing data was high, and we needed to use multiple 
imputation to predict a high percentage of LDL-C and apolipoprotein values. 
Even though the distributions, mean and SD values, and HRs originating from 
the imputed data were similar to the measured data, and are plausible based 
on TC values of those whose data was imputed, these results need careful 
interpretation, because they rely on predicted values. The common limitation 
stems from only one nationality; this weakens the external validity of the 
results considerably. However, the results of Study I and II are biologically 
plausible, and three supporting, but high-risk of bias studies do exist that were 
conducted in the USA.22,24,141
The data used in Studies II, III, and IV comprised only baseline 
measurements, thus indicating that we had limited ability to study risk factors´ 
changes over time. Although only a minor violation in the Cox proportionality 
assumption regarding SBP emerged, birth cohort analysis suggests that during 
long follow-up roughly half the smokers quit.78
results may underestimate the risk-increasing effects of smoking and SBP. 
In addition, the small number of never-smokers with high alcohol 
consumption inhibited reliable inclusion of alcohol consumption in adjusted 
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models.15
drank an equal or nearly equal amount of alcohol as men do, because women 
may be more vulnerable to the adverse effects of alcohol in relation to stroke.158 
However, female aSAH individuals in our cohort drank considerably less than 
men implying that alcohol consumption may not have greatly confounded or 
alcohol consumption and/or years of education as a proxy for SES, which relates 
to alcohol consumption and other cardiovascular disease risk factors159,160 our 
on familial aSAHs, but when the adjusted model included also self-reported 
stroke of any kind in either parent, the results still were the same. Furthermore, 
in all studies from II to IV, some traumatic aSAHs, those included due to 
indexing errors, may have weakened the associations observed. Study IV on 
sudden-death aSAH had no data on individual treatment delays, which could 
bias our results if smoking or high SBP associated with these delays. However, 
our results on sudden-death aSAH endured when our analysis model included 
education as a proxy for SES and marital status, both of which may relate 
to faster recognition of aSAH and thus to shorter treatment delays. Because 
recent studies indicate that aSAH incidence in Finland is similar to that of 
other countries,56,66 the results of Studies II, III, and IV are thus likely to be 
generalizable to populations of European ancestry with similar cardiovascular 
morbidity. 
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1. Methodological limitations in earlier studies explained at least in part 
the paradox stating that low TC elevates aSAH risk.
2. 
men at the population level. 
3. Vulnerability to smoking explained at least in part the elevated aSAH 
risk in women. In both sexes smoking dose-dependently elevated aSAH 
risk, and quitting smoking reduced risk. 
4. 
than it elevated hospitalized aSAH risk. Hospital-based studies may 
not detect all aSAH risk factors and may somewhat underestimate the 
associations of those observed.
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This thesis suggests that methodologically limited aSAH risk-factor studies on 
status quo 
that can be hard to change. As neurosurgical meta-analyses,161 many aSAH risk 
and statistical study methodology that includes more through consideration 
non-linearity, and time-varying covariate analysis. Because accumulating 
with rigorous methodology, and should try to clarify whether lipid-lowering 
medication can reduce aSAH risk in UIA individuals. 
This thesis also suggests that vulnerability to smoking explains, 
at least in part, elevated aSAH risk in women. The prevailing theory relates 
elevated aSAH risk to reduced oestrogen levels, and future studies should 
further investigate this separately in both pre- and post-menopausal women. 
This is important to clarify because of widespread prescription of hormone 
replacement therapy and oral contraceptives. Optimally, future aSAH studies 
should aim at the most unbiased set-up and should include detailed data on 
aSAH risk factors, sudden-death aSAHs, competing risks, major confounders, 
menopause status, hormonal replacement therapy, and oral contraceptives, 
and should measure individual oestrogen levels. These studies could further 
elaborate on whether or not low oestrogen levels, hormonal replacement 
therapy or oral contraceptive use associates with aSAH risk in women. 
In addition to patient and aneurysm characteristics, treatment 
decisions regarding UIAs should at least include assessment of the following 
and history, and should consider also including marital status. Analyses of 
future risk-factor studies should focus on men and women separately and 
include analysis of non-linear associations and potential interactions or 
should focus on the interplay between different aSAH risk factors by using 
analysis methods that can cope with mediation and effectively utilize repeated 
measurements of risk factors. Additionally, with competing risk analysis, 
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future UIA-treatment guideline consortiums should assess how censoring by 
studies of UIA rupture risk. This approach could potentially change the current 
guidelines18 by giving more weight to risk factors. The role of risk factors in UIA 
treatment decisions is likely to grow further, if future studies could include also 
the most severe forms of aSAH: sudden-death aSAH. Implementation of these 
measures has the potential to further expand knowledge of the epidemiology 
and aetiology of aSAH and reduce aSAH morbidity and mortality world-wide.
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